Dendritic Cells as a Nexus for the Development of Multiple Sclerosis and Models of Disease

被引:4
作者
Alakhras, Nada S. S. [1 ]
Kaplan, Mark H. H. [2 ]
机构
[1] Indiana Univ Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr,MS420, Indianapolis, IN 46202 USA
来源
ADVANCED BIOLOGY | 2023年 / 7卷 / 07期
关键词
central nervous systems; dendritic cells; experimental autoimmune encephalomyelitis; multiple sclerosis; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; BLOOD-BRAIN-BARRIER; RANTES MESSENGER-RNA; T-CELLS; CHOROID-PLEXUS; STEADY-STATE; CHEMOKINE RECEPTORS; CEREBROSPINAL-FLUID; CONTROLLED TRIAL;
D O I
10.1002/adbi.202300073
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Multiple sclerosis (MS) results from an autoimmune attack on the central nervous system (CNS). Dysregulated immune cells invade the CNS, causing demyelination, neuronal and axonal damage, and subsequent neurological disorders. Although antigen-specific T cells mediate the immunopathology of MS, innate myeloid cells have essential contributions to CNS tissue damage. Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that promote inflammation and modulate adaptive immune responses. This review focuses on DCs as critical components of CNS inflammation. Here, evidence from studies is summarized with animal models of MS and MS patients that support the critical role of DCs in orchestrating CNS inflammation.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Dendritic cells in the CNS: immune regulators and therapeutic targets for multiple sclerosis treatment
    Zozulya, Alla L.
    Reinke, Emily K.
    Ling, Changying
    Sandor, Matyas
    Fabry, Zsuzsanna
    FUTURE NEUROLOGY, 2007, 2 (01) : 97 - 106
  • [22] Vaccination with autologous dendritic cells: from experimental autoimmune encephalomyelitis to multiple sclerosis
    Link, H
    Huang, YM
    Masterman, T
    Xiao, BG
    JOURNAL OF NEUROIMMUNOLOGY, 2001, 114 (1-2) : 1 - 7
  • [23] Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis
    Liu, Caiyun
    Zhu, Jie
    Mi, Yan
    Jin, Tao
    JOURNAL OF NEUROINFLAMMATION, 2022, 19 (01)
  • [24] The role of natural killer cells in multiple sclerosis and their therapeutic implications
    Chanvillard, Coralie
    Jacolik, Raymond F.
    Infante-Duarte, Carmen
    Nayak, Ramesh C.
    FRONTIERS IN IMMUNOLOGY, 2013, 4
  • [25] Multiple Sclerosis and the Choroid Plexus: Emerging Concepts of Disease Immunopathophysiology
    Dixon, Grant A.
    Perez, Carlos A.
    PEDIATRIC NEUROLOGY, 2020, 103 : 65 - 75
  • [26] Should mast cells be considered therapeutic targets in multiple sclerosis?
    Pinke, Karen Henriette
    Goncalves Zorzella-Pezavento, Sofia Fernanda
    Lara, Vanessa Soares
    Sartori, Alexandrina
    NEURAL REGENERATION RESEARCH, 2020, 15 (11) : 1995 - 2007
  • [27] Pathogenic mechanisms and experimental models of multiple sclerosis
    Slavin, Anthony
    Kelly-Modis, Louise
    Labadia, Mark
    Ryan, Kelli
    Brown, Maryanne L.
    AUTOIMMUNITY, 2010, 43 (07) : 504 - 513
  • [28] "Disease modifying nutricals" for multiple sclerosis
    Schmitz, Katja
    Barthelmes, Julia
    Stolz, Leonie
    Beyer, Susanne
    Diehl, Olaf
    Tegeder, Irmgard
    PHARMACOLOGY & THERAPEUTICS, 2015, 148 : 85 - 113
  • [29] Glutamate, T cells and multiple sclerosis
    Levite, Mia
    JOURNAL OF NEURAL TRANSMISSION, 2017, 124 (07) : 775 - 798
  • [30] Mast cells and angiogenesis in multiple sclerosis
    Ribatti, Domenico
    Tamma, Roberto
    Annese, Tiziana
    INFLAMMATION RESEARCH, 2020, 69 (11) : 1103 - 1110